HD-OPM Archive
Hashtags

#mrna

9 posts

French cohort of 22.7 million: mRNA COVID shots cut COVID death 74%, all-cause death 25%

Dec 05, 2025 · Gokhan Can ♥ 27 · 💬 47 Infections & vaccines

Reports a French cohort of 22.7 million vaccinated and 5.9 million unvaccinated adults followed nearly four years: 74% lower COVID death risk and 25% lower risk of death overall, with no turbocancer signal. The admin adds that vaccination protects against heart disease deaths in high-risk groups and that he prefers flu vaccine to COVID mRNA.

Personalized mRNA vaccine succeeds in phase 3 melanoma trial after ~50% phase 2 benefit

Aug 20, 2026 · Louis Nervegna ♥ 12 · 💬 12 Cancer

A personalized mRNA vaccine plus Keytruda improved recurrence-free and distant metastasis-free survival in a phase 3 trial of more than 1,100 patients with melanoma. The earlier phase 2 trial showed roughly a 50% reduction in recurrence or death at 5 years. Approval might come as early as 2027, and trials are under way in other cancers.

Flu vaccination linked to lower all-cause mortality, per admin's earlier evidence summary

Dec 14, 2025 · Gokhan Can ♥ 10 · 💬 13 Infections & vaccines

Reminder to get vaccinated, linking an earlier admin post. The shared summary lists the flu vaccine with 11-42% lower all-cause mortality in RCTs and prospective cohorts, 43% lower in consistent associations across 40+ studies, and 25-40% lower Alzheimer's risk, citing a cohort study and a systematic review and meta-analysis. Also notes Novavax (non-mRNA) COVID vaccine is no longer available to him.

mRNA-driven Myc and Cyclin T1 restarted heart muscle cell division after heart attack

Nov 14, 2026 · Louis Nervegna ♥ 2 Heart rhythm & heart failure

Louis shares a summary of a Nature Cardiovascular Research study from Cambridge using temporary modified mRNA to activate Myc and Cyclin T1 in heart muscle cells so mature cardiomyocytes re-enter division. The aim is to regenerate heart tissue after a heart attack instead of leaving scar tissue and chronic heart failure. This is early-stage regeneration research.